17beta-Hydroxysteroid Dehydrogenases Involved in Local Oestrogen Synthesis Have Prognostic Significance in Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2005 Feb 3

PMID 15685233

Citations 21

Authors

C Gunnarsson

E Hellqvist

O Stal

Affiliations

Soon will be listed here.

Abstract

The 17beta-hydroxysteroid dehydrogenase (17HSD) enzymes are involved in the local regulation of sex steroids. The 17HSD type 1 enzyme catalyses the interconversion of the weak oestrone (E1) to the more potent oestradiol (E2), whereas 17HSD type 2 catalyses the oxidation of E2 to E1. The aim of this study was to correlate the expression of these enzymes in the tumour with the recurrence-free survival of tamoxifen-treated breast cancer patients. We used real-time reverse transcriptase PCR to investigate the mRNA expression of 17HSD types 1 and 2 in tumour samples from 230 postmenopausal patients. For the patients with oestrogen receptor (ER)-positive breast cancer, we found a statistically significant positive correlation between recurrence-free survival and expression of 17HSD type 2 (P=0.026). We examined the ratio of 17HSD types 2 and 1, and ER-positive patients with low ratios showed a significantly higher rate of recurrence than those with higher ratios (P=0.0047). ER positive patients with high expression levels of 17HSD type 1 had a significantly higher risk for late relapse (P=0.0051). The expression of 17HSD types 1 and 2 in breast cancer differs from the expression of these enzymes in normal mammary gland, and this study indicates that the expression has prognostic significance in breast cancer.

Citing Articles

Minireview: Parabens Exposure and Breast Cancer.

Hager E, Chen J, Zhao L Int J Environ Res Public Health. 2022; 19(3).

PMID: 35162895 PMC: 8834979. DOI: 10.3390/ijerph19031873.

Altered expression of 17‑β‑hydroxysteroid dehydrogenase type 2 and its prognostic significance in non‑small cell lung cancer.

Drzewiecka H, Jarmolowska-Jurczyszyn D, Kluk A, Galecki B, Dyszkiewicz W, Jagodzinski P Int J Oncol. 2020; 56(6):1352-1372.

PMID: 32236582 PMC: 7170045. DOI: 10.3892/ijo.2020.5014.

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.

Romero S, Su H, Satagopan J, Li Q, Seluzicki C, Dries A Breast. 2019; 49:48-54.

PMID: 31678641 PMC: 7375589. DOI: 10.1016/j.breast.2019.10.008.

17β-Hydroxysteroid dehydrogenase 1:2 and breast cancer recurrence: a Danish population-based study.

Collin L, Ulrichsen S, Ahern T, Goodman M, McCullough L, Waller L Acta Oncol. 2019; 59(3):329-333.

PMID: 31671023 PMC: 7033004. DOI: 10.1080/0284186X.2019.1684560.

Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.

Bhardwaj P, Au C, Benito-Martin A, Ladumor H, Oshchepkova S, Moges R J Steroid Biochem Mol Biol. 2019; 189:161-170.

PMID: 30851382 PMC: 6502693. DOI: 10.1016/j.jsbmb.2019.03.002.

References

Speirs V, Green A, Atkin S . Activity and gene expression of 17beta-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8. J Steroid Biochem Mol Biol. 1999; 67(3):267-74. DOI: 10.1016/s0960-0760(98)00119-8. View

Miettinen M, Mustonen M, Poutanen M, Isomaa V, Vihko R . Human 17 beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem J. 1996; 314 ( Pt 3):839-45. PMC: 1217133. DOI: 10.1042/bj3140839. View

Kauraniemi P, Barlund M, Monni O, Kallioniemi A . New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res. 2001; 61(22):8235-40. View

Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y, Noguchi S . Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int J Cancer. 2001; 94(5):685-9. DOI: 10.1002/ijc.1525. View

Dowsett M . Future uses for aromatase inhibitors in breast cancer. J Steroid Biochem Mol Biol. 1997; 61(3-6):261-6. View

Fisher B, Dignam J, Bryant J, Wolmark N . Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001; 93(9):684-90. DOI: 10.1093/jnci/93.9.684. View

Sasano H, Frost A, Saitoh R, Harada N, Poutanen M, Vihko R . Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endocrinol Metab. 1996; 81(11):4042-6. DOI: 10.1210/jcem.81.11.8923858. View

Utsumi T, Yoshimura N, Takeuchi S, Ando J, Maruta M, Maeda K . Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res. 1999; 59(2):377-81. View

Suzuki T, Moriya T, ARIGA N, Kaneko C, Kanazawa M, Sasano H . 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br J Cancer. 2000; 82(3):518-23. PMC: 2363332. DOI: 10.1054/bjoc.1999.0956. View

10.

Purohit A, Newman S, Reed M . The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002; 4(2):65-9. PMC: 138722. DOI: 10.1186/bcr425. View

11.

Gunnarsson C, Olsson B, Stal O . Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res. 2001; 61(23):8448-51. View

12.

Elo J, Harkonen P, Kyllonen A, Lukkarinen O, Poutanen M, Vihko R . Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res. 1997; 57(16):3356-9. View

13.

English M, Stewart P, Hewison M . Estrogen metabolism and malignancy: analysis of the expression and function of 17beta-hydroxysteroid dehydrogenases in colonic cancer. Mol Cell Endocrinol. 2001; 171(1-2):53-60. DOI: 10.1016/s0303-7207(00)00418-4. View

14.

Speirs V, Walton D, Hall M, Atkin S . In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6. Br J Cancer. 1999; 81(4):690-5. PMC: 2362898. DOI: 10.1038/sj.bjc.6690749. View

15.

Koh E, Noda T, Kanaya J, Namiki M . Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate. 2002; 53(2):154-9. DOI: 10.1002/pros.10139. View

16.

Gunnarsson C, Ahnstrom M, Kirschner K, Olsson B, Nordenskjold B, Rutqvist L . Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene. 2003; 22(1):34-40. DOI: 10.1038/sj.onc.1206078. View

17.

Poutanen M, Isomaa V, Lehto V, Vihko R . Immunological analysis of 17 beta-hydroxysteroid dehydrogenase in benign and malignant human breast tissue. Int J Cancer. 1992; 50(3):386-90. DOI: 10.1002/ijc.2910500310. View

18.

Plummer S, Paris M, Myles J, Tubbs R, Crowe J, Casey G . Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors. Genes Chromosomes Cancer. 1997; 20(4):354-62. View

19.

Cleton-Jansen A, Callen D, Seshadri R, Goldup S, McCallum B, Crawford J . Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Res. 2001; 61(3):1171-7. View

20.

Schiff R, Massarweh S, Shou J, Bharwani L, Mohsin S, Osborne C . Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004; 10(1 Pt 2):331S-6S. DOI: 10.1158/1078-0432.ccr-031212. View